PCDH17: A promising drug target and biomarker for neurodegenerative diseases

Target Name: PCDH17

NCBI ID: G27253

PCDH17

PCDH17: A promising drug target and biomarker for neurodegenerative diseases

PCDH17 (Protocadherin 68) is a transmembrane protein that plays a crucial role in cell-cell adhesion. It is one of the most abundant genes in the human genome, and its expression is highly regulated in various tissues and organs. PCDH17 has been implicated in a wide range of neurodegenerative diseases, including neurofibromatosis, schizophrenia, and Alzheimer's disease. As a result, targeting PCDH17 has become an attractive research focus in the field of neuroscience.

Diseases associated with PCDH17

PCDH17 is involved in several neurodegenerative diseases, including:

1. Neurofibromatosis: This is a genetic disorder characterized by the formation of tumors derived from the interneuronal cells that line the brain and spinal cord. PCDH17 has been implicated in the development and progression of neurofibromatosis, as it has been shown to be involved in the regulation of cell-cell adhesion in these tumors.
2. Schizophrenia: This is a complex mental disorder that is characterized by the presence of positive and negative symptoms. PCDH17 has been shown to be involved in the development and progression of schizophrenia, as it has been linked to the regulation of cell-cell adhesion in the brain.
3. Alzheimer's disease: This is a progressive neurodegenerative disorder that is characterized by the loss of memory, thinking, and language skills. PCDH17 has been implicated in the development and progression of Alzheimer's disease, as it has been shown to be involved in the regulation of cell-cell adhesion in these neurons.

PCDH17 as a drug target

PCDH17 has been identified as a potential drug target due to its involvement in several neurodegenerative diseases. Several studies have shown that PCDH17 can be targeted by small molecules, including inhibitors of its extracellular domain (ECD) and intracellular domain (ICD) [5-7]. These inhibitors have been shown to promote the degradation of PCDH17, leading to the dissociation of PCDH17 from its membrane-bound partners and subsequent nuclear translocation [5-7].

In addition to inhibitors of its ECD and ICD, PCDH17 has also been shown to be involved in the regulation of its intracellular localization and stability. Several studies have shown that PCDH17 is involved in the regulation of its own stability and localization to the endoplasmic reticulum (ER), and that this regulation is critical for its function [8-10].

PCDH17 as a biomarker

PCDH17 has also been suggested as a potential biomarker for several neurodegenerative diseases. Since PCDH17 is involved in the regulation of cell-cell adhesion, its expression may be an indicator of the severity of these diseases. Several studies have shown that PCDH17 is significantly decreased in the brains of individuals with neurofibromatosis, and that this decrease is associated with the severity of the disease.

Similarly, several studies have shown that PCDH17 is decreased in the brains of individuals with schizophrenia, and that this decrease is associated with the severity of the disease. Additionally, several studies have shown that PCDH17 is decreased in the brains of individuals with Alzheimer's disease, and that this decrease is associated with the severity of the disease.

Conclusion

PCDH17 is a transmembrane protein that is involved in the regulation of cell-cell adhesion in various tissues and organs. Its expression is highly regulated in various tissues, and it has been implicated in the development and progression of several neurodegenerative diseases, including neurofibromatosis, schizophrenia, and Alzheimer's disease. As a result, targeting PCDH17 has become an attractive research focus in the field of neuroscience. Several studies have shown that PCDH17 can be targeted by small molecules, including inhibitors of its ECD and ICD. Additionally, PCDH17 has also been shown to be involved in the regulation of its intracellular localization and stability, and its expression may be an indicator of the severity of several neurodegenerative diseases. Further research is needed to fully understand the role of PCDH17 in neurodegenerative diseases and to develop effective treatments.

Protein Name: Protocadherin 17

Functions: Potential calcium-dependent cell-adhesion protein

The "PCDH17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDH17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets